Sanjay Bambhaniya · May 19, 2026

Q-Line Biotech SME IPO Live Subscription Status

SME Book Build Listed

Healthcare

NSE SME

Price Band

₹326 - ₹343

Issue Size

₹214.48 Cr

Lot Size

400 shares

Min. Investment

₹1,37,200

Live GMP ₹117

34.11% Est. Listing: ₹460

SIP Calc Compare

IPO Timeline

DRHP FILED —

OPEN May 21, 2026

CLOSE May 25, 2026

ALLOTMENT May 26, 2026

LISTING May 29, 2026

IPO DETAILS REVIEW GMP SUBSCRIPTION ALLOTMENT STATUS

Q-Line Biotech Subscription

Day-wise bidding details from NSE SME

Live bidding details · Updated every 10 minutes

Live - Day 4 20th Jul 2026 12:29

QIB

123.94 ×

Qualified Institutional

Oversubscribed

NII

145.98 ×

Non-Institutional

Oversubscribed

S-HNI

81.35 ×

Small HNI (Below ₹10L)

Oversubscribed

B-HNI

178.29 ×

Big HNI (Above ₹10L)

Oversubscribed

RETAIL (RII)

71.44 ×

Individual Investors

Oversubscribed

OVERALL

102.42 ×

Final Subscription

Oversubscribed

Stay updated on the latest subscription status of Q-Line Biotech IPO:
We ensure you receive up-to-date subscription information curated from official sources (NSE SME). Q-Line Biotech IPO Subscription is Closed Now . Visit this section to get accurate data on shares offered vs. shares bid for QIB, NII, Retail, and other sub-categories.

Day-wise Subscription

Real time

Day	QIB	NII	S-HNI	B-HNI	RII	TOTAL
Day 1	4.15x	5.25x	4.05x	5.85x	3.65x	4.13x
Day 2	5.19x	15.61x	10.90x	17.96x	9.94x	9.80x
Day 3	123.94x	145.98x	81.35x	178.29x	71.44x	102.42x
Day 4	123.94x	145.98x	81.35x	178.29x	71.44x	102.42x

Shares Offered vs Bid

NSE SME Data

Category	Shares Offered	Shares Bid	Bid Amount (₹ Cr)
QIB	11,88,000	14,72,37,200	5,050.24
NII	8,91,600	13,01,53,600	4,464.27
— S-HNI	2,97,200	2,41,77,600	829.29
— B-HNI	5,94,400	10,59,76,000	3,634.98
RII	20,79,200	14,85,32,800	5,094.68
Total	4158800	425923600	14,609.18

Anchor Investor Allocation

Anchor investors are big institutions that buy shares before the public. The Book Running Lead Manager finalised the allocation of 17,81,200 Equity Shares to Anchor Investors at ₹343 per share.

Anchor Investor Details
Bid Date	Wed, May 20, 2026
Shares Offered	17,81,200
Anchor Portion (₹ Cr.)	61.10 Cr.
Anchor lock-in period shares (30 Days)	8,90,600
Anchor lock-in period end date for remaining shares (90 Days)	8,90,600

Sr.	Anchor	Group Entity	Shares Allotted	Amt (₹ cr.)	% Allocated	% Allotment of Issue
1	ABAKKUS SMALL CАР FUND	ABAKKUS	2,91,600	10	16.37	4.66
2	CARNELIAN AIF CATEGORY I TRUST-Scheme I	CARNELIAN	2,81,600	9.66	15.81	4.5
3	ABAKKUS FLEXI EDGE FUND 1	ABAKKUS	2,27,600	7.81	12.78	3.64
4	BHARAT VENTURE OPPORTUNITIES FUND	BHARAT VENTURE	2,00,000	6.86	11.23	3.2
5	INDIA MAX INVESTMENT FUND LTD.	INDIA MAX INVESTMENT FUND LTD.	1,43,200	4.91	8.04	2.29
6	SANSHI FUND-I	SANSHI	1,43,200	4.91	8.04	2.29
7	MERU INVESTMENT FUND PCC-CELL 1	MERU INVESTMENT	87,600	3	4.92	1.4
8	TIGER STRATEGIES FUND 1	TIGER STRATEGIES	58,400	2	3.28	0.93
9	FINAVENUE CAPITAL TRUST-FINAVENUE GROWTH FUND	FINAVENUE	57,200	1.96	3.21	0.91
10	HEM GROWTH OPPORTUNITIES FUND	HEM GROWTH OPPORTUNITIES FUND	57,200	1.96	3.21	0.91
11	360 ONE LVF TREASURY SOLUTIONS FUND	360 ONE	29,200	1	1.64	0.47
12	HDFC BANK LTD.	HDFC BANK	29,200	1	1.64	0.47
13	INNOVATIVE VISION FUND	INNOVATIVE VISION	29,200	1	1.64	0.47
14	NAVBHARAT INVESTMENT TRUST-NAVBHARAT INVESTMENT OPPORTUNITIES FUND	NAVBHARAT	29,200	1	1.64	0.47
15	RAJASTHAN GLOBAL SECURITIES PVT.LTD.	RAJASTHAN GLOBAL SECURITIES	29,200	1	1.64	0.47
16	RELIGO COMMODITIES VENTURES TRUST-RELIGO COMMODITIES VENTURE FUND	RELIGO	29,200	1	1.64	0.47
17	SUNRISE INVESTMENT TRUST-SUNRISE INVESTMENT OPPORTUNITIES FUND	SUNRISE	29,200	1	1.64	0.47
18	TATTVAM AIF TRUST-Aanjay Ageless AIF Fund	TATTVAM	29,200	1	1.64	0.47

Disclaimer: This information is for educational purposes only. Always seek advice from a qualified financial professional before making investment choices.

Sanjay Bambhaniya

Sanjay has 8+ years of experience in data-driven IPO insights. His expertise in digital marketing and web development complements his financial knowledge and helps him to develop effective fintech solutions. He is an entrepreneur and director who helps investors understand complex primary market trends in easy-to-understand IPO reports, news, and updates.

Discussion & Feedback

0 Comments

No comments yet. Be the first to share your thoughts!

Q-Line Biotech SME IPO Live Subscription Status

Q-Line Biotech Subscription

Day-wise Subscription

Shares Offered vs Bid

Anchor Investor Allocation

In the Spotlight

Media Feature